Assets of Affinium13 Feb 2014 14:32
The Board of International Biotechnology Trust plc (the "Company") notes that agreement has been reached to sell the assets of Affinium Pharmaceuticals, an unquoted portfolio company, to Debiopharm Group.
The Directors have changed the valuation of the Company's interest in this unquoted company from £0.8m to £1.8m on a cost of £0.8m to reflect this deal. This change in valuation will be included in the Company's Net Asset Value ("NAV") at close of business today and will be included within the NAV released to the market tomorrow. The increase in NAV per share in comparison to that released today is 1.76 pence per share.